Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Drospirenone/estradiol

Angeliq (Drospirenone/Estradiol). Schering Health Care Ltd. UK Summary of product characteristics, December 2006. [Pg.977]

Drospirenone 3 mg (+30 meg ethinyl estradiol) by mouth on days 1-21 of the menstrual cycle31 As noted with other OCs above drospirenone may contribute to hyperkalemia in patients with reduced renal function... [Pg.759]

A randomized, double-blind, placebo-controlled trial evaluating the use of a monophasic OC containing 30 meg ethinyl estradiol and 3 mg drospirenone, a progesterone with anti-androgenic effects, showed improvement in the treatment arm compared with placebo.31 In particular, appetite, food cravings, and acne improved. However, active treatment was not associated with a statistically significant improvement in the overall outcome measure, the Calendar of Premenstrual Experiences (COPE) scale, perhaps because of the small sample size (n = 82). [Pg.762]

Drospirenone/Ethinyl Estradiol (YAZ) Estradiol C5pionate Medrox5progestCTone Acetate (LuneUe)... [Pg.52]

Drospirenone/ethinyl estradiol Moderate female acne See also Chapter 39. [Pg.1307]

Drospirenone/ ethinyl estradiol 3 mg/0.03 mg Tablet Oral contraceptives... [Pg.19]

Inner phase Drug Up to 1% Ethinyl estradiol 0.0375% Drospirenone 3.75%... [Pg.77]

Cibula D, Weidenhammer HG, et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethynyl estradiol 20 pg and drospirenone 3 mg. Clin Drug Invest 2006 26 143-150. [Pg.2111]

Preston RA, Alonso A, Panzitta D, Zhang P, Kaiara AH. Additive effect of drospirenone/17-fl-estradiol in hypertensive postmenopausal women receiving enalapril. AmJHypertens(2(Xl2)... [Pg.880]

Bird ST, Delaney JA, EtminanM, BrophyJM, Hartzema AG. Drospirenone and non-fatal venous thromboembolism is there a risk difference by dosage of ethinyl-estradiol J Thromb Haemost 2013 ll(6) 1059-68. [Pg.632]

Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17p-estradiol in postmenopausal women. Climacteric 2013 16(4) 490-8. [Pg.632]

See other pages where Drospirenone/estradiol is mentioned: [Pg.53]    [Pg.142]    [Pg.142]    [Pg.52]    [Pg.142]    [Pg.142]    [Pg.52]    [Pg.142]    [Pg.142]    [Pg.53]    [Pg.142]    [Pg.142]    [Pg.52]    [Pg.142]    [Pg.142]    [Pg.52]    [Pg.142]    [Pg.142]    [Pg.739]    [Pg.745]    [Pg.341]    [Pg.53]    [Pg.158]    [Pg.257]    [Pg.905]    [Pg.52]    [Pg.158]    [Pg.328]    [Pg.1451]    [Pg.1479]    [Pg.52]    [Pg.158]    [Pg.2085]    [Pg.2087]    [Pg.2088]    [Pg.880]    [Pg.1141]    [Pg.411]   
See also in sourсe #XX -- [ Pg.142 ]

See also in sourсe #XX -- [ Pg.142 ]

See also in sourсe #XX -- [ Pg.142 ]



SEARCH



Drospirenone

Drospirenone/ethinyl estradiol

Estradiol

© 2024 chempedia.info